Korean J Hepatol.
1997 Jun;3(2):114-122.
The Comparision of Propranolol Monotherapy
and Propranolol , Isosorbide-5-mononitrate and Metoclopramide Triple Therapy
after Endoscopic Sclerotherapy in Patients with Esophageal Variceal Bleeding
Abstract
- BACKGROUND/AIMS
Hemorrlmge from esophageal varices is a catastrophic complication of portal hypertension. Sclentherapy and/or pharmacological reatment have been used in the primary and secondary pevention of hemorrhages in high-risk cirrhotic patients. We compared the efficacy of propranolol with the efficacy of propranolol plus isosorbide mononitrate plus metoclopramide for the prevention of variceal rebleeding
METHODS
Forty-six hospitalized patients with cirrhosis and bleeding from esaphageal varices were treated with mhscopic sclerotherapy and randomly assigned to treatment with propranolol (25 patients: group 1) or propranolol plus isosorbide-5-mononitrate plus metoclopramide (21 patients: group 2). The primary outcomes were rebleeding and death.
RESULTS
Base-line data were similar in the two groups, and the median follow-up
was 15.4 months. Seventeen (68%) of 25 patients in group 1 and 11 (52%) of 21 patients
in group 2 had repeated bleeding from varices during the follow-up period,
but thae were no significant statistical differences between two groups.
1 he 2-year survival rate of both poups were 56% (14/25) in poup 1 and 62%
(13/21) in group 2 during follow-up period. The causes of death in both groups
wererebleeding (6/11: group 1 vs 3/8: group 2), hepatic failure (3/11: group 1 vs
3/8: group 2), and hepatoma (1/11: group 1 vs 1/8: group 2).
CONCLUSIONS
Propranolol plus isosorbide mononitrate plus metoclopramide triple
therapy did not differ from propranolol monotherapy in the aspects of rebleeding
and survival in patients with esophageal variceal bleeding after endoscopic sclerotherapy,
although the former revealed the tendency of the decrease in rebleeding and mortality rate.